Blueprint Medicines
2025
$9.1B
Why
Added Ayvakit for systemic mastocytosis and a pipeline in KIT-driven diseases.
Impact
Expanded Sanofi's rare immunology portfolio.
Outcome
Completed July 18, 2025; about $9.1B upfront plus contingent value rights.
Sanofi S.A.
Pharmaceuticals and BiotechnologyFounded 2004- HQ today: Paris, France
Reviewed by Swet Parvadiya
Company data updated: October 2026
Acquisitions
Sanofi Acquisitions
4
Major Deals Covered
$32.1B
Disclosed Deal Value
What are Sanofi's biggest acquisitions?
Sanofi's largest disclosed acquisition here is Genzyme for $20.1B in 2011. This page covers 4 major deals from 2004 to 2025, each with its price where disclosed and the reason behind it.
- Major deals covered
- 4
- Largest deal
- Genzyme ($20.1B)
- First deal
- 2004
- Most recent
- 2025
| Company | Year | Price | Purpose |
|---|---|---|---|
| Aventis | 2004 | Undisclosed | Sanofi-Synthélabo launched a hostile bid for the larger Franco-German Aventis, with French government support for a domestic combination. |
| Genzyme | 2011 | $20.1B | Added a rare disease and biologics business based in Cambridge, Massachusetts. |
| Provention Bio | 2023 | $2.9B | Acquired Tzield, which can delay stage 3 type 1 diabetes. |
| Blueprint Medicines | 2025 | $9.1B | Added Ayvakit for systemic mastocytosis and a pipeline in KIT-driven diseases. |
- What companies has Sanofi bought?
- Major acquisitions by Sanofi documented here include Genzyme (2011), Blueprint Medicines (2025), Provention Bio (2023) and Aventis (2004).
- What is Sanofi's most recent acquisition?
- The most recent Sanofi acquisition documented here is Blueprint Medicines, in 2025, for $9.1B.
Provention Bio
2023
$2.9B
Why
Acquired Tzield, which can delay stage 3 type 1 diabetes.
Impact
Added an autoimmune diabetes product to specialty care.
Outcome
Tzield is part of Sanofi's pharma launches portfolio.
Genzyme
2011
$20.1B
Why
Added a rare disease and biologics business based in Cambridge, Massachusetts.
Impact
Brought enzyme therapies such as Cerezyme and Fabrazyme.
Outcome
Genzyme remains the base of Sanofi's rare disease franchise.
Aventis
2004
Why
Sanofi-Synthélabo launched a hostile bid for the larger Franco-German Aventis, with French government support for a domestic combination.
Impact
Created Sanofi-Aventis, Europe's largest drugmaker at the time.
Outcome
The deal defined the modern group; the company was renamed Sanofi in 2011.
Sanofi S.A.'s Growth & Acquisition Strategy
Sanofi's strategy, set under Paul Hudson's 2019 'Play to Win' plan and now being tightened by Belén Garijo, is to concentrate on immunology, rare diseases, neurology and vaccines. Key steps were exiting most diabetes and cardiovascular research, separating consumer health (Opella, majority sold to CD&R in April 2025) and buying specialty assets such as Provention Bio (2023), Inhibrx's AATD drug (2024) and Blueprint Medicines (2025). Garijo has stressed execution discipline and capital allocation, and in Q2 2026 she discontinued several late-stage programs.
How Sanofi S.A. Makes Money
Sanofi makes money by developing, manufacturing and selling prescription medicines and vaccines to hospitals, pharmacies, wholesalers, insurers and government health systems. In 2025 its ~$49.3 billion (EUR43.6 billion) of net sales broke down into Dupixent (~$17.7 billion (EUR15.7 billion)), pharma launches such as ALTUVIIIO and Ayvakit (~$4.41 billion (EUR3.9 billion)), vaccines (~$8.93 billion (EUR7.9 billion)) and other established medicines (~$18.2 billion (EUR16.1 billion)). The United States generated ~$25.1 billion (EUR22.2 billion) and Europe ~$10.4 billion (EUR9.2 billion). Dupixent profits are shared with Regeneron under their long-running antibody collaboration.
Sanofi Acquisitions FAQ
What was the largest acquisition in Sanofi's corporate history?
Sanofi's largest transaction was the historic hostile acquisition of Franco-German pharmaceutical giant Aventis in August 2004 for €55 billion ($65 billion), creating Sanofi-Aventis, the third-largest pharmaceutical company in the world.
What was the significance of the $20.1 billion Genzyme acquisition in 2011?
In 2011, Sanofi acquired Boston-based Genzyme for $20.1 billion, instantly transforming Sanofi into a global powerhouse in rare genetic disease enzyme replacement therapies and multiple sclerosis.
What was the acquisition of Bioverativ in 2018?
In January 2018, Sanofi acquired Biogen spinoff Bioverativ for $11.6 billion in cash, acquiring extended half-life hemophilia therapies Eloctate and Alprolix.
Why did Sanofi acquire Ablynx for €3.9 billion in 2018?
In 2018, Sanofi acquired Belgian biotechnology firm Ablynx for €3.9 billion, gaining its proprietary "Nanobody" single-domain antibody platform and Cablivi (caplacizumab) for acquired thrombotic thrombocytopenic purpura (aTTP).
What was the acquisition of Kymab in 2021 and what asset did it bring?
In April 2021, Sanofi acquired British biotech Kymab for $1.1 billion upfront plus $350 million in milestones, acquiring amlitelimab (an OX40L antibody in Phase 3 trials for atopic dermatitis and asthma), viewed as a potential €5B+ blockbuster.
Why did Sanofi acquire Translate Bio for $3.2 billion in 2021?
Sanofi acquired mRNA therapeutics developer Translate Bio for $3.2 billion in September 2021 to secure full ownership of proprietary mRNA formulation technology and create its in-house mRNA Center of Excellence.
What was the acquisition of Kadmon Holdings in 2021?
In November 2021, Sanofi acquired Kadmon Holdings for $1.9 billion, adding Rezurock (belumosudil), a first-in-class treatment for chronic graft-versus-host disease (cGVHD) in transplant patients.
What was the 2016 asset swap between Sanofi and Boehringer Ingelheim?
In December 2016, Sanofi and Boehringer Ingelheim completed a historic €22 billion asset swap: Sanofi transferred its animal health business (Merial, valued at €11.4B) to Boehringer in exchange for Boehringer's consumer healthcare business (valued at €6.7B) plus €4.7B in cash.
What was the acquisition of Provention Bio in 2023?
In April 2023, Sanofi acquired Provention Bio for $2.9 billion, acquiring Tzield (teplizumab), the first and only FDA-approved therapy capable of delaying the onset of Stage 3 clinical type 1 diabetes in at-risk children and adults.
What was the €16 billion Opella transaction in 2024?
In October 2024, Sanofi agreed to sell a 50% controlling interest in Opella (its Consumer Healthcare division) to US private equity firm CD&R for an enterprise value of ~€16 billion, refocusing Sanofi purely on innovative prescription biopharma.
What is Sanofi's core criteria when evaluating M&A targets?
Sanofi targets clinical-stage or commercial biotechnology assets that fit squarely into its four core therapeutic pillars: immunology, neurology/rare diseases, oncology, and vaccines, with potential for first-in-class or best-in-class market leadership.
How does Sanofi fund its multi-billion-dollar acquisitions?
Sanofi funds M&A using a combination of strong balance sheet operating cash flow, low-coupon euro-denominated commercial paper, and investment-grade corporate bonds, maintaining an A1/AA- credit rating.
Related M&A Histories
Compare corporate acquisition records, deal values, and strategic targets
Explore Sanofi
Core profile pages, founders and related research hubs for this company.